COMPASS THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
COMPASS THERAPEUTICS, INC. (CMPX) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $2.04 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-03-05
- COMPASS THERAPEUTICS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2025 was $2.04M, a 28.60% decline from fiscal 2024.
- COMPASS THERAPEUTICS, INC. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2024 was $2.86M.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month |
|---|---|
| 2025-12-31 | $2.04M 10-K · filed 2026-03-05 |
| 2024-12-31 | $2.86M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |